Education
About Us
Working with TipRanks
Follow Us
Kiora Pharmaceuticals (KPRX)
NASDAQ:KPRX
KPRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.51 - $5.55
Previous CloseN/A
Volume13.46K
Average Volume (3M)9.78K
Market Cap
$9.06M
Enterprise Value-$16.83M
Total Cash (Recent Filing)$31.28M
Total Debt (Recent Filing)$94.30K
Price to Earnings (P/E)4.4
Beta0.74
Next Earnings
May 07, 2025EPS Estimate
-0.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.71
Shares Outstanding3,000,788
10 Day Avg. Volume6,346
30 Day Avg. Volume9,775
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.62
Price to Cash Flow (P/CF)2.70
P/FCF Ratio2.70
Enterprise Value/Market Cap-1.86
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.05
Enterprise Value/Ebitda-2.83
Forecast
1Y Price Target
$10.00Price Target Upside220.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Kiora Pharmaceuticals News
PremiumCompany Announcements
Kiora Pharmaceuticals Advances Retinal Disease Pipeline
PremiumCompany Announcements
Kiora Pharmaceuticals Gains Approval for Phase 2 Trial
PremiumCompany Announcements
Kiora Pharmaceuticals Announces Board Appointment, Regains Nasdaq Compliance---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe company has received approval to initiate the Phase 2 ABACUS-2 trial of KIO-301 in retinitis pigmentosa.
Financial PositionThe company had $26.8M in cash and investments, which may be sufficient to fund operations into 2027.
PartnershipsKiora has secured a partnership with Laboratoires Théa with a $16M upfront payment and potential milestones up to $285M, indicating strong commercial support.
Bears Say
Clinical RisksRisks include the failure of KIO-301 in clinical trials, to secure regulatory approval, or to achieve commercial success due to reimbursement, penetration rate, and competition.
Financial PerformanceFor 4Q24, net loss was $4.2M, higher than the estimated loss of $2.7M.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KPRX FAQ
What was Kiora Pharmaceuticals’s price range in the past 12 months?
Kiora Pharmaceuticals lowest stock price was $2.51 and its highest was $5.55 in the past 12 months.
What is Kiora Pharmaceuticals’s market cap?
Kiora Pharmaceuticals’s market cap is $9.06M.
When is Kiora Pharmaceuticals’s upcoming earnings report date?
Kiora Pharmaceuticals’s upcoming earnings report date is May 07, 2025 which is in 12 days.
How were Kiora Pharmaceuticals’s earnings last quarter?
Kiora Pharmaceuticals released its earnings results on Mar 25, 2025. The company reported -$1.21 earnings per share for the quarter, missing the consensus estimate of -$0.55 by -$0.66.
Is Kiora Pharmaceuticals overvalued?
According to Wall Street analysts Kiora Pharmaceuticals’s price is currently Undervalued.
Does Kiora Pharmaceuticals pay dividends?
Kiora Pharmaceuticals does not currently pay dividends.
What is Kiora Pharmaceuticals’s EPS estimate?
Kiora Pharmaceuticals’s EPS estimate is -0.67.
How many shares outstanding does Kiora Pharmaceuticals have?
Kiora Pharmaceuticals has 3,000,788 shares outstanding.
What happened to Kiora Pharmaceuticals’s price movement after its last earnings report?
Kiora Pharmaceuticals reported an EPS of -$1.21 in its last earnings report, missing expectations of -$0.55. Following the earnings report the stock price went down -5%.
Which hedge fund is a major shareholder of Kiora Pharmaceuticals?
Currently, no hedge funds are holding shares in KPRX
---
Company Description
Kiora Pharmaceuticals
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.
---
KPRX Stock 12 Month Forecast
Average Price Target
$10.00
▲(220.51% Upside)
Technical Analysis
Neurometrix
―
Eterna Therapeutics
―
PharmaCyte Biotech
―
Lyra Therapeutics
―
Acurx Pharmaceuticals
―
Best Analysts Covering KPRX
1 Year
1 Year Success Rate
0/15 ratings generated profit
1 Year Average Return
-54.83%
reiterated a buy rating 29 days ago
Copying Yi Chen's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -54.83% per trade.
---